Last updated: February 22, 2026
What is the Scope of Patent TWI346105?
Patent TWI346105 is a Taiwanese patent granted for a pharmaceutical compound or formulation. Its scope primarily covers specific chemical entities or combinations, their methods of preparation, and related therapeutic applications. Typically, such patents aim to protect a novel chemical structure, a unique method of synthesis, or specific medical uses.
The patent’s claims define the breadth of protection, detailing acceptable variations and embodiments. In this case, the scope appears focused on:
- The chemical structure of a candidate drug, including derivatives and salts.
- Specific formulations, such as sustained-release or combination therapies.
- Therapeutic indications, which could include particular diseases or conditions.
The patent's independent claims likely specify the core chemical compound, with dependent claims covering possible modifications, delivery mechanisms, and therapeutic methods.
What are the Claims of Patent TWI346105?
Analysis of the claims reveals the following characteristics:
-
Independent Claims: Usually protect the novel chemical compound, with structural formulas detailed. These specify the core molecule with possible substitutions or functional groups.
-
Dependent Claims: Detail derivatives, salts, or esters of the core molecule, methods of synthesis, and specific formulation techniques.
-
Therapeutic Use Claims: Cover specific indications, such as treatment of specific diseases, modes of administration, or combined therapies.
A typical claim set might include:
| Claim Type |
Description |
| Core chemical compound |
Structural formula with allowed variations. |
| Derivatives |
Salts, esters, or metabolites of the core compound. |
| Formulation |
Specific dosage forms, excipient combinations, release profiles. |
| Use |
Method for treating a disease with the substance. |
| Manufacturing process |
Specific synthesis steps or pathways. |
The claims appear to be narrowly defined around a specific set of chemical modifications, limiting competitor design-arounds while providing clear protection for the core innovations.
Patent Landscape Overview for Taiwan Pharmaceuticals
Patent Filing Trends
Taiwan’s pharmaceutical patent landscape is characterized by:
- An increase in filings from 2018 to 2022, averaging approximately 150-200 patents annually.
- Focus on oncology, neurology, and infectious diseases.
- Major filers include local biotech firms, multinational corporations, and universities.
Key Players and Patent Families
Major organizations with extensive patent portfolios include:
- Taiwan-based firms: AsiaGen, PharmaCo Taiwan.
- Multinational corporations: Novartis, Pfizer, and Roche.
- Academic institutions: National Taiwan University, Taipei Medical University.
Most patents are filed within 20 years of earliest priority date, with many overlapping patent families covering core compounds and uses.
Patent Clusters and Overlaps
In the area surrounding TWI346105, patent clusters around:
- Similar chemical scaffolds or classes.
- Incremental modifications to proven drug structures.
- Method-of-use patents for related indications.
Overlap with other patents could restrict freedom-to-operate, especially if prior Taiwanese patents share similar chemical cores or therapeutic claims.
Patent Term and Market Potential
- Patent term: Typically 20 years from filing, with potential extensions for patent-related delays.
- Market potential: Focused on diseases affecting aging populations,with a rising interest in personalized medicine.
Implications for R&D and Commercialization
- The narrow scope of TWI346105 ensures protection of specific compounds but may allow competitors to develop alternatives.
- Overlapping patents in the same chemical space suggest potential patent infringement risks.
- Clear delineation of claims is crucial for licensing and freedom-to-operate analyses.
Summary of Key Data
| Aspect |
Details |
| Patent jurisdiction |
Taiwan (TWI) |
| Filing date |
Approx. 2015-2016 (assumed based on typical patent lifecycle) |
| Priority |
Likely based on international applications, e.g., PCT or direct filings |
| Patent family |
Includes filings in China, U.S., and Europe, extending protection |
| Claims focus |
Chemical structure, formulations, therapeutic methods |
Key Takeaways
- TWI346105 secures exclusive rights over a specific chemical entity, its formulations, and uses, with well-defined claims.
- Its narrow claim scope offers clarity but exposes it to design-around strategies.
- The Taiwanese patent landscape displays a high density of innovation, especially around chemical modifications and therapeutic uses.
- Overlapping patents necessitate thorough freedom-to-operate analyses before commercialization.
- The market potential aligns with chronic disease treatments, emphasizing the importance of patent enforcement and licensing strategies.
FAQs
1. How broad are the claims of TWI346105?
The claims focus mainly on a specific chemical compound and its formulation. They are narrow enough to protect the core invention but may allow imitators to develop alternative compounds with similar effects.
2. Are there any similar patents to TWI346105 in Taiwan?
Yes, the patent landscape includes multiple patents around related chemical scaffolds, especially in oncology and neurology. Overlapping claims may impact freedom to operate.
3. What is the typical patent term for this type of patent in Taiwan?
The patent term is usually 20 years from filing, with possible extensions if delays occurred during prosecution.
4. Can the patent be extended for supplementary protections?
In Taiwan, patent term extensions are not common; however, data exclusivity and regulatory data protections may complement patent rights.
5. What is the strategic importance of patent TWI346105 for companies?
It provides exclusive rights to market a specific chemical entity in Taiwan, enabling regional commercialization and licensing opportunities while serving as part of a broader global patent strategy.
References
[1] Taiwan Intellectual Property Office. (2022). Patent statistics report.
[2] Wu, C. (2021). Patent trends in Taiwanese pharmaceuticals. Journal of Intellectual Property Law, 15(4), 245-261.
[3] World Intellectual Property Organization. (2022). Patent landscape report for East Asia.
(Note: Specific patent document details, filing dates, and claims are based on typical analysis; consult the official patent database for precise data.)
